BioNTech Records Stupendous Q2 Sales, Earnings Growth; Estimates FY21 COVID-19 Vaccine Revenues Of €15B

BioNTech SE reports Q2 FY21 revenues of €5.31 billion compared to €41.7 million a year ago, primarily due to an increase in the supply of COVID-19 vaccine worldwide. Revenues more than doubled from €2.04 billion sales in Q1 FY21.